Table 2.

Efficacy and safety of NOACs compared with warfarin in patients with AF aged 75 y or older

Trial acronymComparisonsNumber of patients ≥75 yStroke/SEEMajor bleedingIntracranial bleeding
HR (95% CI)HR (95% CI)HR (95% CI)
RE-LY DE 150 mg bid vs warfarin 7258 0.67 (0.49-0.90) 1.18 (0.98-1.42) 0.42 (0.25-0.70) 
DE 110 mg bid* vs warfarin 0.88 (0.66-1.17) 1.01 (0.83-1.23) 0.37 (0.21-0.64) 
ROCKET-AF Rivaroxaban daily vs warfarin 6229 0.80 (0.63-1.02) 1.11 (0.92-1.34) 0.80 (0.50-1.28) 
ARISTOTLE Apixaban bid vs warfarin 5678 0.71 (0.53-0.95) 0.64 (0.52-0.79) 0.34 (0.20-0.57) 
ENGAGE-AF Edoxaban 60 mg daily vs warfarin 8474 0.83 (0.66-1.04) 0.83 (0.70-0.99) 0.40 (0.26 -0.62) 
Edoxaban 30 mg† daily vs warfarin* 1.12 (0.91-1.37) 0.47 (0.38 -0.58) 0.31 (0.19-0.49) 
Trial acronymComparisonsNumber of patients ≥75 yStroke/SEEMajor bleedingIntracranial bleeding
HR (95% CI)HR (95% CI)HR (95% CI)
RE-LY DE 150 mg bid vs warfarin 7258 0.67 (0.49-0.90) 1.18 (0.98-1.42) 0.42 (0.25-0.70) 
DE 110 mg bid* vs warfarin 0.88 (0.66-1.17) 1.01 (0.83-1.23) 0.37 (0.21-0.64) 
ROCKET-AF Rivaroxaban daily vs warfarin 6229 0.80 (0.63-1.02) 1.11 (0.92-1.34) 0.80 (0.50-1.28) 
ARISTOTLE Apixaban bid vs warfarin 5678 0.71 (0.53-0.95) 0.64 (0.52-0.79) 0.34 (0.20-0.57) 
ENGAGE-AF Edoxaban 60 mg daily vs warfarin 8474 0.83 (0.66-1.04) 0.83 (0.70-0.99) 0.40 (0.26 -0.62) 
Edoxaban 30 mg† daily vs warfarin* 1.12 (0.91-1.37) 0.47 (0.38 -0.58) 0.31 (0.19-0.49) 

bid, twice daily; DE, dabigatran etexilate; SEE, systemic embolic event.

*

Dabigatran 110 mg is not approved in the United States for stroke prevention in AF.

†

Edoxaban 30 mg is not approved in many countries.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal